8 Einträge gefunden

1. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

   1. Lonial, Sagar
   2. Popat, Rakesh
   3. Hulin, Cyrille
   4. Jagannath, Sundar
   5. Oriol, Albert
   6. Richardson, Paul G
   7. Facon, Thierry

   2022 - Forschungsinformationssystem des UKE
2. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

   1. Davies, Faith E
   2. Pawlyn, Charlotte
   3. Usmani, Saad Z
   4. San-Miguel, Jesus F
   5. Einsele, Hermann
   6. Boyle, Eileen M
   7. Corre, Jill

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

   1. Munshi, Nikhil C
   2. Anderson, Larry D
   3. Shah, Nina
   4. Madduri, Deepu
   5. Berdeja, Jesús
   6. Lonial, Sagar
   7. Raje, Noopur

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

   1. Dimopoulos, Meletios A
   2. Lonial, Sagar
   3. White, Darrell
   4. Moreau, Philippe
   5. Weisel, Katja
   6. San-Miguel, Jesus
   7. Shpilberg, Ofer

   2020 - Forschungsinformationssystem des UKE
7. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

   1. Lonial, Sagar
   2. Lee, Hans C
   3. Badros, Ashraf
   4. Trudel, Suzanne
   5. Nooka, Ajay K
   6. Chari, Ajai
   7. Abdallah, Al-Ola

   2020 - Forschungsinformationssystem des UKE
8. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

   1. Chari, Ajai
   2. Vogl, Dan T
   3. Gavriatopoulou, Maria
   4. Nooka, Ajay K
   5. Yee, Andrew J
   6. Huff, Carol A
   7. Moreau, Philippe

   2019 - Forschungsinformationssystem des UKE